Table 3.
Percentage of patients that developed adverse effects to TKI
| Unwanted effect | Afatinib (n = 40) | Erlotinib (n = 26) | Gefitinib (n = 33) | |||
|---|---|---|---|---|---|---|
| Any Grade | Grade 3–4 | Any Grade | Grade 3–4 | Any Grade | Grade 3–4 | |
| Any unwanted effect | 36 (90%) | 3 (7.5%) | 26 (100%) | 4 (15.4%) | 26 (78.8%) | 1 (3%) |
| • Rash | 23 (57.5%) | 1 (2.5%) | 13 (50%) | 1 (3.8%) | 13 (39.4%) | 0 (0.0%) |
| • Diarrhea | 14 (35%) | 2 (5%) | 13 (50%) | 2 (7.7%) | 18 (54.5%) | 0 (0.0%) |
| • Xerosis | 16 (40%) | 0 (0.0%) | 9 (34.6%) | 0 (0.0%) | 12 (36.4%) | 0 (0.0%) |
| • Paronychia | 11 (27.5%) | 0 (0.0%) | 4 (15.4%) | 0 (0.0%) | 4 (12.1%) | 0 (0.0%) |
| • Nausea | 3 (7.5%) | 0 (0.0%) | 7 (26.9%) | 0 (0.0%) | 7 (21.2%) | 0 (0.0%) |
| • Acne | 6 (15%) | 0 (0.0%) | 6 (23.1%) | 0 (0.0%) | 1 (3%) | 0 (0.0%) |
| • Fatigue | 5 (12.5%) | 0 (0.0%) | 6 (23.1%) | 0 (0.0%) | 2 (6.1%) | 0 (0.0%) |
| • Stomatitis | 6 (15%) | 0 (0.0%) | 5 (19.2%) | 0 (0.0%) | 5 (15.2%) | 0 (0.0%) |
| • Constipation | 2 (5%) | 0 (0.0%) | 4 (15.4%) | 0 (0.0%) | 3 (9.1%) | 0 (0.0%) |
| • Vomit | 2 (5%) | 0 (0.0%) | 3 (11.5%) | 0 (0.0%) | 1 (3%) | 0 (0.0%) |
| • Alopecia | 1 (2.5%) | 0 (0.0%) | 0 (0%) | 0 (0.0%) | 3 (9.1%) | 1 (3%) |
| • Neuropathy | 2 (5%) | 0 (0.0%) | 0 (0%) | 0 (0.0%) | 3 (9.1%) | 0 (0.0%) |
| • Anorexia | 3 (7.5%) | 0 (0.0%) | 0 (0%) | 0 (0.0%) | 1 (3%) | 0 (0.0%) |
| • Liver toxicity | 0 (0%) | 0 (0.0%) | 1 (3.8%) | 0 (0.0%) | 0 (0%) | 0 (0.0%) |
| • Anemia | 0 (0%) | 0 (0.0%) | 0 (0%) | 0 (0.0%) | 1 (3%) | 0 (0.0%) |
| • Arthralgia | 1 (2.5%) | 0 (0.0%) | 0 (0%) | 0 (0.0%) | 1 (3%) | 0 (0.0%) |